Autoimmune lymphoproliferative syndrome other imaging findings: Difference between revisions
| Line 10: | Line 10: | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
uptake of FDG in the various subgroups of ALPS without lymphoma appears visually and quantitatively to overlap with findings in ALPS patients with HL and NHL. Even intense FDG uptake does not by itself merit biopsy or signify lymphoma in ALPS, and hence routine FDG imaging of these patients is not indicated. Despite this, when lymphoma is suspected on clinical grounds, FDG imaging can be used to guide biopsy choice of an affected lymph node based on maximum FDG avidity. Furthermore, in those patients with active lymphoma, FDG can still be utilized to assess for tumor response and relapse, as it is done in other lymphomas. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 22:52, 3 July 2021
|
Autoimmune lymphoproliferative syndrome Microchapters |
|
Differentiating Autoimmune lymphoproliferative syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune lymphoproliferative syndrome other imaging findings On the Web |
|
American Roentgen Ray Society Images of Autoimmune lymphoproliferative syndrome other imaging findings |
|
FDA on Autoimmune lymphoproliferative syndrome other imaging findings |
|
CDC on Autoimmune lymphoproliferative syndrome other imaging findings |
|
Autoimmune lymphoproliferative syndrome other imaging findings in the news |
|
Blogs on Autoimmune lymphoproliferative syndrome other imaging findings |
|
Directions to Hospitals Treating Autoimmune lymphoproliferative syndrome |
|
Risk calculators and risk factors for Autoimmune lymphoproliferative syndrome other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Fluorodeoxyglucose positron emission tomography (FDG-PET) may be helpful in the diagnosis of Autoimmune lymphoproliferative syndrome(ALPS) by distinguishing benign lymphadenopathy from malignant lymphadenopathy.
Other Imaging Findings
uptake of FDG in the various subgroups of ALPS without lymphoma appears visually and quantitatively to overlap with findings in ALPS patients with HL and NHL. Even intense FDG uptake does not by itself merit biopsy or signify lymphoma in ALPS, and hence routine FDG imaging of these patients is not indicated. Despite this, when lymphoma is suspected on clinical grounds, FDG imaging can be used to guide biopsy choice of an affected lymph node based on maximum FDG avidity. Furthermore, in those patients with active lymphoma, FDG can still be utilized to assess for tumor response and relapse, as it is done in other lymphomas.